The Zacks Analyst Blog Highlights:MasterCard, Discover Financial Services,
Fidelity National Information Services, Global Payments and Novartis
CHICAGO, Jan. 24, 2013
CHICAGO, Jan. 24, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include MasterCard Incorporated
(NYSE:MA), Discover Financial Services (NYSE:DFS), Fidelity National
Information Services (NYSE:FIS), Global Payments Inc. (NYSE:GPN) and Novartis
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday's Analyst Blog:
MasterCard for Easier EMV Migration
MasterCard Incorporated (NYSE:MA) recently decided to provide other U.S. debit
networks with the some of the payment technology solutions it owns. MasterCard
took such a step to support the prevalent trend of acceptance of EMV solutions
(EMV stands for Europay, MasterCard and Visa).
Through this deal the company will allow debit networks, merchants, acquirers
and processors to have access to MasterCard's market-ready EMV solution. As a
result, financial institutions can start issuing EMV cards immediately. This
would save precious time for these institutions which otherwise would have to
strive for new standards.
MasterCard will open this technology by allowing all debit networks within the
United States to use their brand name for the payments processed through
Maestro AID (application identifier).
MasterCard has been undertaking deals for some time now to promote electronic
payment solutions in the U.S. Through this current move, the company aims to
reduce chip entry costs and complications in implementing EMV. As a result
merchants and acquirers will be able to maximize their investments and select
their debit networks. This will give them an upper hand in the contemporary
processing system where migration to EMV cards is much in vogue.
Earlier in December 2012, MasterCard joined hands with mobile wallet and
transactions platform provider C-SAM to deliver mobile commerce solutions to
MasterCard is expected to release its fourth-quarter and full year 2012
earnings results on Jan 31. The Zacks Consensus Estimate for the fourth
quarter of 2012 is pegged at $4.79, up 18.9% year over year. Earnings for the
full year 2012 are expected at $21.99, up 17.6 % year over year.
Earlier this month, Discover Financial Services (NYSE:DFS) launched the new
Cadence Bank Debit Card through its alliance with Birmingham-based Cadence
Bank. Through this alliance, Discover Debit will provide network support to
the Cadence debit card holders in the second quarter of the year.
MasterCard carries a Zacks Rank #3 (Hold). Payment processors Fidelity
National Information Services (NYSE:FIS) and Global Payments Inc. (NYSE:GPN)
carry a favorable Zacks Rank #2 (Buy) and are worth noting.
Positive CHMP Opinions for Novartis
Novartis' (NYSE:NVS) global eye care division, Alcon, recently received a
positive opinion from the Committee for Medicinal Products for Human Use
(CHMP) for Jetrea (ocriplasmin). Jetrea is under review in the EU for the
treatment of vitreomacular traction (VMT) including instances where the
macular hole diameter is less than or equal to 400 microns.
The CHMP's opinion was based on data submitted from two pivotal phase III
studies which showed that Jetrea successfully resolved VMT and macular hole
compared to placebo.
Belgian biopharmaceutical company ThromboGenics had granted Novartis the
rights to commercialize Jetrea outside the US. In Oct 2012, Novartis' Jetrea
was approved for the treatment of patients with symptomatic vitreomacular
adhesion (VMA) in the US, where it was launched earlier this year.
Novartis estimates that 250,000 to 300,000 patients in Europe suffer from
visual distortion, decreased visual acuity and central blindness. This
represents significant commercial potential for Jetrea, which should be able
to capture a share of the European market considering the limited treatment
options available for VMT. With the CHMP in favor of approving Jetrea, we
expect EU approval for the candidate shortly.
Meanwhile, Novartis received a positive opinion from the CHMP for another of
its candidates, llaris (canakinumab, ACZ885). Ilaris is under review in the EU
for the treatment of patients with acute gouty arthritis and suffering from
frequent attacks, and whose symptoms were not managed with current treatment
options. A final decision on Ilaris should be out shortly.
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.